Crossject Société Anonyme (EPA:ALCJ)

France flag France · Delayed Price · Currency is EUR
2.050
-0.050 (-2.38%)
At close: Feb 27, 2026
15.69%
Market Cap 108.12M
Revenue (ttm) 4.07M
Net Income (ttm) -11.26M
Shares Out 52.74M
EPS (ttm) -0.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 228,024
Average Volume 361,679
Open 2.100
Previous Close 2.100
Day's Range 2.010 - 2.140
52-Week Range 0.720 - 2.695
Beta 0.56
RSI 49.36
Earnings Date Mar 27, 2026

About Crossject Société Anonyme

Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. In addition, the company is dev... [Read more]

Sector Healthcare
Founded 2001
Employees 103
Stock Exchange Euronext Paris
Ticker Symbol ALCJ
Full Company Profile

Financial Performance

In 2024, Crossject Société Anonyme's revenue was 4.12 million, an increase of 6.28% compared to the previous year's 3.87 million. Losses were -12.80 million, 48.1% more than in 2023.

Financial Statements

News

There is no news available yet.